# Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis

> **NCT00310492** · PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 154 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** subcutaneous immunotherapy

## Key facts

- **NCT ID:** NCT00310492
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-05
- **Final completion:** 2009-11
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2015-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310492, "Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00310492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*